Graves Ophthalmopathy Market
Graves Ophthalmopathy Market Infographic

Graves Ophthalmopathy Market Overview

The most common extrathyroidal symptom of Graves' illness is ophthalmopathy, sometimes called thyroid-associated ophthalmopathy and thyroid eye disease. This autoimmune condition causes the orbit to become inflamed as a result of the generation of autoantibodies. The thyroid and orbit both share a protein that the autoantibodies are thought to target.

Graves Ophthalmopathy Epidemiology Segmentation in the 7MM from 2019 to 2032

  • Prevalent Cases
  • Diagnosed Prevalent Cases
  • Gender-specific Diagnosed Prevalent Cases
  • Diagnosed Prevalent Cases by Chronicity
  • Moderate-to-severe Drug-treated Cases of Acute Graves’ Ophthalmopathy

Graves Ophthalmopathy Epidemiology Insights (2022)

The Total Graves Ophthalmopathy prevalent cases in the 7MM were ~2.3 million cases in 2022

Graves Ophthalmopathy Market Insight (2022)

The Graves Ophthalmopathy Market size in the 7MM was valued ~USD 2 billion in 2022

Graves Ophthalmopathy Market Strengths

  • Recent FDA approval of Horizon’s TEPEZZA
  • Efforts to increase patient and clinician awareness

Graves Ophthalmopathy Market Opportunities

  • Lack of availability of disease-modifying treatment
  • Development of ocular drug discovery programs

Graves Ophthalmopathy Emerging Drugs and key companies

  • Batoclimab (IMVT 1401): Immunovant Sciences
  • COSENTYX (secukinumab): Novartis
  • VRDN-001: Viridian Therapeutics
  • Linsitinib: Sling Therapeutics
  • Aflibercept: Regeneron Pharmaceuticals
  • VB421: ValenzaBio, and others